Zastaprazan
A pharmaceutical drug used as a proton pump inhibitor
Zastaprazan is a pharmaceutical compound that functions as a proton pump inhibitor (PPI). It is primarily used in the treatment of conditions related to excessive stomach acid production, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease.
Mechanism of Action[edit | edit source]
Zastaprazan works by inhibiting the H+/K+ ATPase enzyme system, commonly known as the gastric proton pump, located in the parietal cells of the stomach lining. This inhibition prevents the final step in the production of gastric acid, thereby reducing acid secretion. By decreasing stomach acidity, Zastaprazan helps in alleviating symptoms associated with acid-related disorders and promotes healing of the gastric mucosa.
Pharmacokinetics[edit | edit source]
Zastaprazan is administered orally and is absorbed in the small intestine. It is a prodrug that is activated in the acidic environment of the parietal cells. The drug is metabolized in the liver, primarily by the cytochrome P450 enzyme system, and is excreted through the kidneys.
Clinical Uses[edit | edit source]
Zastaprazan is indicated for the treatment of:
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Erosive esophagitis
Side Effects[edit | edit source]
Common side effects of Zastaprazan include headache, nausea, diarrhea, abdominal pain, and dizziness. Long-term use of proton pump inhibitors, including Zastaprazan, may be associated with an increased risk of osteoporosis-related fractures, Clostridium difficile infection, and hypomagnesemia.
Drug Interactions[edit | edit source]
Zastaprazan may interact with other medications that are metabolized by the cytochrome P450 system. It can also affect the absorption of drugs that require an acidic environment for optimal absorption, such as ketoconazole and iron supplements.
Development and Approval[edit | edit source]
Zastaprazan is developed by pharmaceutical companies focusing on novel treatments for acid-related disorders. It is subject to regulatory approval processes in various countries, where its safety and efficacy are evaluated through clinical trials.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
